Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist
Background/Objectives Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hyp...
Gespeichert in:
| Veröffentlicht in: | International Journal of Obesity 2022-03, Vol.46 (3), p.623-629 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 629 |
|---|---|
| container_issue | 3 |
| container_start_page | 623 |
| container_title | International Journal of Obesity |
| container_volume | 46 |
| creator | Shoemaker, Ashley H. Silver, Heidi J. Buchowski, Maciej Slaughter, James C. Yanovski, Jack A. Elfers, Clinton Roth, Christian L. Abuzzahab, M. Jennifer |
| description | Background/Objectives
Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hypothesized GLP1RA therapy in patients with HO would cause both lower energy intake and increased energy expenditure.
Subjects/Methods
Forty-two patients aged 10-26 years (median 16 years) with HO with suprasellar tumors were randomized to GLP1RA (exenatide extended release once-weekly, ExQW,
n
= 23) or placebo (
n
= 19). Thirty seven (81%) patients completed the 36-week double-blind placebo-controlled trial. Total energy expenditure (TEE) was measured with doubly labeled water, physical activity was assessed with actigraphy, and intake was estimated with
ad libitum
buffet meal. Results are presented as adjusted mean between-group difference.
Results
As compared with treatment with placebo, treatment with ExQW was associated with decreased energy intake during a buffet meal (−1800 kJ (−430 kcal), 95% CI −3 184 to −418 kJ,
p
= 0.02). There were no significant differences in physical activity between groups. ExQW (vs. placebo) treatment was associated with a decrease in TEE (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day,
p
|
| doi_str_mv | 10.1038/s41366-021-01043-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8881399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2616279795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-2de4ea131810a655d229928c2ba9c777c39acc86a7cac30118dd1f79e8b3f8ab3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EokPhD7BAltiwcfEj8WODhKpSkEaCRbu2HOfOjEsSB9vTKv--LlNK6YKVZZ_vnnuvD0JvGT1hVOiPuWFCSkI5I5TRRhD5DK1YoyRpG6OeoxUVVBHayvYIvcr5ilLatpS_REei6i1r5AqFswnSdsGdG9zkAYcJ75Y5ll29j8Hj2EEOZbl7T5DnOGXAJeKSwJURpoJvQtlhh2MtJjcAP4cFn69_EFZxD3OJCbttnEIur9GLjRsyvLk_j9Hll7OL069k_f382-nnNfGNagrhPTTgmGCaUSfbtufcGK4975zxSikvjPNeS6e884IypvuebZQB3YmNdp04Rp8OvvO-G6H3dcjkBjunMLq02OiC_VeZws5u47XVWjNhTDX4cG-Q4q895GLHkD0M9YMg7rPlkkmujDJtRd8_Qa_iPk11vUoJ3hiumKoUP1A-xZwTbB6GYdTeJWkPSdqapP2dpJW16N3jNR5K_kRXAXEAcpWmLaS_vf9jewtFvKry</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2632492717</pqid></control><display><type>article</type><title>Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist</title><source>MEDLINE</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Shoemaker, Ashley H. ; Silver, Heidi J. ; Buchowski, Maciej ; Slaughter, James C. ; Yanovski, Jack A. ; Elfers, Clinton ; Roth, Christian L. ; Abuzzahab, M. Jennifer</creator><creatorcontrib>Shoemaker, Ashley H. ; Silver, Heidi J. ; Buchowski, Maciej ; Slaughter, James C. ; Yanovski, Jack A. ; Elfers, Clinton ; Roth, Christian L. ; Abuzzahab, M. Jennifer</creatorcontrib><description>Background/Objectives
Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hypothesized GLP1RA therapy in patients with HO would cause both lower energy intake and increased energy expenditure.
Subjects/Methods
Forty-two patients aged 10-26 years (median 16 years) with HO with suprasellar tumors were randomized to GLP1RA (exenatide extended release once-weekly, ExQW,
n
= 23) or placebo (
n
= 19). Thirty seven (81%) patients completed the 36-week double-blind placebo-controlled trial. Total energy expenditure (TEE) was measured with doubly labeled water, physical activity was assessed with actigraphy, and intake was estimated with
ad libitum
buffet meal. Results are presented as adjusted mean between-group difference.
Results
As compared with treatment with placebo, treatment with ExQW was associated with decreased energy intake during a buffet meal (−1800 kJ (−430 kcal), 95% CI −3 184 to −418 kJ,
p
= 0.02). There were no significant differences in physical activity between groups. ExQW (vs. placebo) treatment was associated with a decrease in TEE (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day,
p
< 0.01, adjusted for baseline TEE). The treatment effect was still significant after further adjustment for change in body composition (−372 kJ/day (−89 kcal/day), 95% CI −699 to −42 kJ/day,
p
= 0.04) or change in leptin (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day,
p
< 0.01). This decrease in TEE occurred despite an increase in lean mass and fat mass (1.7 vs. 1.3 kg lean mass,
p
= 0.88 and 1.5 vs. 4.6 kg fat mass,
p
= 0.04, ExQW vs. placebo).
Conclusions
Treatment with a GLP1RA was associated with a decrease in food intake but also a decrease in TEE that was disproportionate to change in body composition.</description><identifier>ISSN: 0307-0565</identifier><identifier>EISSN: 1476-5497</identifier><identifier>DOI: 10.1038/s41366-021-01043-6</identifier><identifier>PMID: 34975146</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/443/319/1488/1562 ; 692/699/2743/393 ; Adolescent ; Adult ; Agonists ; Body composition ; Body fat ; Child ; Energy ; Energy balance ; Energy expenditure ; Energy Intake ; Energy Metabolism ; Epidemiology ; Exenatide - therapeutic use ; Food intake ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide-1 Receptor - agonists ; Health Promotion and Disease Prevention ; Humans ; Hypothalamus ; Internal Medicine ; Leptin ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Obesity ; Obesity - complications ; Obesity - drug therapy ; Patients ; Physical activity ; Placebos ; Public Health ; Receptors ; Satiety ; Tumors ; Young Adult</subject><ispartof>International Journal of Obesity, 2022-03, Vol.46 (3), p.623-629</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-2de4ea131810a655d229928c2ba9c777c39acc86a7cac30118dd1f79e8b3f8ab3</citedby><cites>FETCH-LOGICAL-c474t-2de4ea131810a655d229928c2ba9c777c39acc86a7cac30118dd1f79e8b3f8ab3</cites><orcidid>0000-0001-8542-1637 ; 0000-0003-3037-4057 ; 0000-0003-1628-3677 ; 0000-0002-0566-1743</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41366-021-01043-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41366-021-01043-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34975146$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shoemaker, Ashley H.</creatorcontrib><creatorcontrib>Silver, Heidi J.</creatorcontrib><creatorcontrib>Buchowski, Maciej</creatorcontrib><creatorcontrib>Slaughter, James C.</creatorcontrib><creatorcontrib>Yanovski, Jack A.</creatorcontrib><creatorcontrib>Elfers, Clinton</creatorcontrib><creatorcontrib>Roth, Christian L.</creatorcontrib><creatorcontrib>Abuzzahab, M. Jennifer</creatorcontrib><title>Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist</title><title>International Journal of Obesity</title><addtitle>Int J Obes</addtitle><addtitle>Int J Obes (Lond)</addtitle><description>Background/Objectives
Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hypothesized GLP1RA therapy in patients with HO would cause both lower energy intake and increased energy expenditure.
Subjects/Methods
Forty-two patients aged 10-26 years (median 16 years) with HO with suprasellar tumors were randomized to GLP1RA (exenatide extended release once-weekly, ExQW,
n
= 23) or placebo (
n
= 19). Thirty seven (81%) patients completed the 36-week double-blind placebo-controlled trial. Total energy expenditure (TEE) was measured with doubly labeled water, physical activity was assessed with actigraphy, and intake was estimated with
ad libitum
buffet meal. Results are presented as adjusted mean between-group difference.
Results
As compared with treatment with placebo, treatment with ExQW was associated with decreased energy intake during a buffet meal (−1800 kJ (−430 kcal), 95% CI −3 184 to −418 kJ,
p
= 0.02). There were no significant differences in physical activity between groups. ExQW (vs. placebo) treatment was associated with a decrease in TEE (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day,
p
< 0.01, adjusted for baseline TEE). The treatment effect was still significant after further adjustment for change in body composition (−372 kJ/day (−89 kcal/day), 95% CI −699 to −42 kJ/day,
p
= 0.04) or change in leptin (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day,
p
< 0.01). This decrease in TEE occurred despite an increase in lean mass and fat mass (1.7 vs. 1.3 kg lean mass,
p
= 0.88 and 1.5 vs. 4.6 kg fat mass,
p
= 0.04, ExQW vs. placebo).
Conclusions
Treatment with a GLP1RA was associated with a decrease in food intake but also a decrease in TEE that was disproportionate to change in body composition.</description><subject>631/443/319/1488/1562</subject><subject>692/699/2743/393</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Agonists</subject><subject>Body composition</subject><subject>Body fat</subject><subject>Child</subject><subject>Energy</subject><subject>Energy balance</subject><subject>Energy expenditure</subject><subject>Energy Intake</subject><subject>Energy Metabolism</subject><subject>Epidemiology</subject><subject>Exenatide - therapeutic use</subject><subject>Food intake</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide-1 Receptor - agonists</subject><subject>Health Promotion and Disease Prevention</subject><subject>Humans</subject><subject>Hypothalamus</subject><subject>Internal Medicine</subject><subject>Leptin</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Patients</subject><subject>Physical activity</subject><subject>Placebos</subject><subject>Public Health</subject><subject>Receptors</subject><subject>Satiety</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0307-0565</issn><issn>1476-5497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtv1DAUhS0EokPhD7BAltiwcfEj8WODhKpSkEaCRbu2HOfOjEsSB9vTKv--LlNK6YKVZZ_vnnuvD0JvGT1hVOiPuWFCSkI5I5TRRhD5DK1YoyRpG6OeoxUVVBHayvYIvcr5ilLatpS_REei6i1r5AqFswnSdsGdG9zkAYcJ75Y5ll29j8Hj2EEOZbl7T5DnOGXAJeKSwJURpoJvQtlhh2MtJjcAP4cFn69_EFZxD3OJCbttnEIur9GLjRsyvLk_j9Hll7OL069k_f382-nnNfGNagrhPTTgmGCaUSfbtufcGK4975zxSikvjPNeS6e884IypvuebZQB3YmNdp04Rp8OvvO-G6H3dcjkBjunMLq02OiC_VeZws5u47XVWjNhTDX4cG-Q4q895GLHkD0M9YMg7rPlkkmujDJtRd8_Qa_iPk11vUoJ3hiumKoUP1A-xZwTbB6GYdTeJWkPSdqapP2dpJW16N3jNR5K_kRXAXEAcpWmLaS_vf9jewtFvKry</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Shoemaker, Ashley H.</creator><creator>Silver, Heidi J.</creator><creator>Buchowski, Maciej</creator><creator>Slaughter, James C.</creator><creator>Yanovski, Jack A.</creator><creator>Elfers, Clinton</creator><creator>Roth, Christian L.</creator><creator>Abuzzahab, M. Jennifer</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7TK</scope><scope>7TS</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8542-1637</orcidid><orcidid>https://orcid.org/0000-0003-3037-4057</orcidid><orcidid>https://orcid.org/0000-0003-1628-3677</orcidid><orcidid>https://orcid.org/0000-0002-0566-1743</orcidid></search><sort><creationdate>20220301</creationdate><title>Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist</title><author>Shoemaker, Ashley H. ; Silver, Heidi J. ; Buchowski, Maciej ; Slaughter, James C. ; Yanovski, Jack A. ; Elfers, Clinton ; Roth, Christian L. ; Abuzzahab, M. Jennifer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-2de4ea131810a655d229928c2ba9c777c39acc86a7cac30118dd1f79e8b3f8ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/443/319/1488/1562</topic><topic>692/699/2743/393</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Agonists</topic><topic>Body composition</topic><topic>Body fat</topic><topic>Child</topic><topic>Energy</topic><topic>Energy balance</topic><topic>Energy expenditure</topic><topic>Energy Intake</topic><topic>Energy Metabolism</topic><topic>Epidemiology</topic><topic>Exenatide - therapeutic use</topic><topic>Food intake</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide-1 Receptor - agonists</topic><topic>Health Promotion and Disease Prevention</topic><topic>Humans</topic><topic>Hypothalamus</topic><topic>Internal Medicine</topic><topic>Leptin</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Patients</topic><topic>Physical activity</topic><topic>Placebos</topic><topic>Public Health</topic><topic>Receptors</topic><topic>Satiety</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shoemaker, Ashley H.</creatorcontrib><creatorcontrib>Silver, Heidi J.</creatorcontrib><creatorcontrib>Buchowski, Maciej</creatorcontrib><creatorcontrib>Slaughter, James C.</creatorcontrib><creatorcontrib>Yanovski, Jack A.</creatorcontrib><creatorcontrib>Elfers, Clinton</creatorcontrib><creatorcontrib>Roth, Christian L.</creatorcontrib><creatorcontrib>Abuzzahab, M. Jennifer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International Journal of Obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shoemaker, Ashley H.</au><au>Silver, Heidi J.</au><au>Buchowski, Maciej</au><au>Slaughter, James C.</au><au>Yanovski, Jack A.</au><au>Elfers, Clinton</au><au>Roth, Christian L.</au><au>Abuzzahab, M. Jennifer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist</atitle><jtitle>International Journal of Obesity</jtitle><stitle>Int J Obes</stitle><addtitle>Int J Obes (Lond)</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>46</volume><issue>3</issue><spage>623</spage><epage>629</epage><pages>623-629</pages><issn>0307-0565</issn><eissn>1476-5497</eissn><abstract>Background/Objectives
Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hypothesized GLP1RA therapy in patients with HO would cause both lower energy intake and increased energy expenditure.
Subjects/Methods
Forty-two patients aged 10-26 years (median 16 years) with HO with suprasellar tumors were randomized to GLP1RA (exenatide extended release once-weekly, ExQW,
n
= 23) or placebo (
n
= 19). Thirty seven (81%) patients completed the 36-week double-blind placebo-controlled trial. Total energy expenditure (TEE) was measured with doubly labeled water, physical activity was assessed with actigraphy, and intake was estimated with
ad libitum
buffet meal. Results are presented as adjusted mean between-group difference.
Results
As compared with treatment with placebo, treatment with ExQW was associated with decreased energy intake during a buffet meal (−1800 kJ (−430 kcal), 95% CI −3 184 to −418 kJ,
p
= 0.02). There were no significant differences in physical activity between groups. ExQW (vs. placebo) treatment was associated with a decrease in TEE (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day,
p
< 0.01, adjusted for baseline TEE). The treatment effect was still significant after further adjustment for change in body composition (−372 kJ/day (−89 kcal/day), 95% CI −699 to −42 kJ/day,
p
= 0.04) or change in leptin (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day,
p
< 0.01). This decrease in TEE occurred despite an increase in lean mass and fat mass (1.7 vs. 1.3 kg lean mass,
p
= 0.88 and 1.5 vs. 4.6 kg fat mass,
p
= 0.04, ExQW vs. placebo).
Conclusions
Treatment with a GLP1RA was associated with a decrease in food intake but also a decrease in TEE that was disproportionate to change in body composition.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34975146</pmid><doi>10.1038/s41366-021-01043-6</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8542-1637</orcidid><orcidid>https://orcid.org/0000-0003-3037-4057</orcidid><orcidid>https://orcid.org/0000-0003-1628-3677</orcidid><orcidid>https://orcid.org/0000-0002-0566-1743</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-0565 |
| ispartof | International Journal of Obesity, 2022-03, Vol.46 (3), p.623-629 |
| issn | 0307-0565 1476-5497 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8881399 |
| source | MEDLINE; Nature Journals Online; SpringerLink Journals - AutoHoldings |
| subjects | 631/443/319/1488/1562 692/699/2743/393 Adolescent Adult Agonists Body composition Body fat Child Energy Energy balance Energy expenditure Energy Intake Energy Metabolism Epidemiology Exenatide - therapeutic use Food intake GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Health Promotion and Disease Prevention Humans Hypothalamus Internal Medicine Leptin Medicine Medicine & Public Health Metabolic Diseases Obesity Obesity - complications Obesity - drug therapy Patients Physical activity Placebos Public Health Receptors Satiety Tumors Young Adult |
| title | Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Energy%20balance%20in%20hypothalamic%20obesity%20in%20response%20to%20treatment%20with%20a%20once-weekly%20GLP-1%20receptor%20agonist&rft.jtitle=International%20Journal%20of%20Obesity&rft.au=Shoemaker,%20Ashley%20H.&rft.date=2022-03-01&rft.volume=46&rft.issue=3&rft.spage=623&rft.epage=629&rft.pages=623-629&rft.issn=0307-0565&rft.eissn=1476-5497&rft_id=info:doi/10.1038/s41366-021-01043-6&rft_dat=%3Cproquest_pubme%3E2616279795%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2632492717&rft_id=info:pmid/34975146&rfr_iscdi=true |